Comparing Mural Oncology (NASDAQ:MURA) and Dominari (NASDAQ:DOMH)

Mural Oncology (NASDAQ:MURA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Volatility & Risk

Mural Oncology has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Insider and Institutional Ownership

80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 2.2% of Mural Oncology shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Mural Oncology and Dominari’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-83.39%	-70.70%
Dominari	-167.73%	-91.67%	-77.80%

Analyst Recommendations

This is a summary of recent ratings and target prices for Mural Oncology and Dominari, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0	2	2	0	2.50
Dominari	0	0	0	0	0.00

Mural Oncology currently has a consensus price target of $12.00, indicating a potential upside of 363.32%. Given Mural Oncology’s stronger consensus rating and higher possible upside, research analysts clearly believe Mural Oncology is more favorable than Dominari.

Valuation & Earnings

This table compares Mural Oncology and Dominari”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mural Oncology	N/A	N/A	-$128.51 million	($7.67)	-0.34
Dominari	$18.15 million	4.25	-$14.70 million	($4.50)	-1.17

Dominari has higher revenue and earnings than Mural Oncology. Dominari is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Mural Oncology beats Dominari on 9 of the 13 factors compared between the two stocks.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.